GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Oncotherapy PLC (LSE:AVO) » Definitions » Median PS Value

Advanced Oncotherapy (LSE:AVO) Median PS Value : £0.00 (As of May. 16, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Advanced Oncotherapy Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Advanced Oncotherapy's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 was £0. Advanced Oncotherapy's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is £0.00.

As of today (2024-05-16), Advanced Oncotherapy's share price is £0.01925. Advanced Oncotherapy's Median PS Value is £0.00. Therefore, Advanced Oncotherapy's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Advanced Oncotherapy's Median PS Value or its related term are showing as below:

LSE:AVO's Price-to-Median-PS-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.82
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Advanced Oncotherapy Median PS Value Historical Data

The historical data trend for Advanced Oncotherapy's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Oncotherapy Median PS Value Chart

Advanced Oncotherapy Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Advanced Oncotherapy Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Advanced Oncotherapy's Median PS Value

For the Medical Devices subindustry, Advanced Oncotherapy's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Oncotherapy's Price-to-Median-PS-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced Oncotherapy's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Advanced Oncotherapy's Price-to-Median-PS-Value falls into.



Advanced Oncotherapy Median PS Value Calculation

Advanced Oncotherapy's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0*
=0.00

10-Year Median PS Ratio is .
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Advanced Oncotherapy's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 was £0.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advanced Oncotherapy  (LSE:AVO) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Advanced Oncotherapy's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=0.01925/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advanced Oncotherapy Median PS Value Related Terms

Thank you for viewing the detailed overview of Advanced Oncotherapy's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Oncotherapy (LSE:AVO) Business Description

Traded in Other Exchanges
N/A
Address
4 Tenterden Street, Third Floor, London, GBR, W1S 1TE
Advanced Oncotherapy PLC is active in the healthcare domain in the United Kingdom. As a medical care provider, its focus is to develop technologies to maximize the destructive effect of radiation on tumors whilst minimizing damage to healthy tissues. It develops an affordable proton-based radiotherapy system, using innovative and clinically effective technology, thereby contributing to curing critical unmet conditions. The company's only business segment is Proton Therapy.